A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06771271. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Non-Randomized, Open-label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7200220 in Monotherapy and in Combination With Ranibizumab Following Intravitreal Administration in Patients With Diabetic or Uveitic Macular Edema
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to assess the safety and tolerability of RO7200220 as monotherapy (diabetic macular edema \[DME\] or uveitic macular edema \[UME\] population) and in combination with ranibizumab (DME population only).
Study identification
- NCT ID
- NCT06771271
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 85 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 22, 2019 (Actual)
- Primary completion
- Nov 13, 2023 (Actual)
- Completion
- Nov 13, 2023 (Actual)
- Last update posted
- Jan 13, 2025
2019 – 2023
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Retina-Vitreous Associates Medical Group | Beverly Hills | California | 90211 | — |
| California Retina Consultants | Oxnard | California | 93036 | — |
| Retina Institute of California Medical Group d/b/a Acuity Eye Group | Palm Desert | California | 92260 | — |
| Byers Eye Insitute at Stanford | Palo Alto | California | 94303 | — |
| Florida Eye Associates | Melbourne | Florida | 32901 | — |
| Retina Vitreous Assoc of FL | St. Petersburg | Florida | 33711 | — |
| Illinois Retina Associates SC | Oak Park | Illinois | 60304 | — |
| Cumberland Valley Retina PC | Hagerstown | Maryland | 21740 | — |
| Sierra Eye Associates | Reno | Nevada | 89502 | — |
| Wake Forest Baptist Medical Center | Winston-Salem | North Carolina | 27157 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Oregon HSU | Portland | Oregon | 97239 | — |
| Mid Atlantic Retina | Philadelphia | Pennsylvania | 19107 | — |
| Retina Res Institute of Texas | Abilene | Texas | 79606 | — |
| Austin Clinical Research LLC | Austin | Texas | 78750 | — |
| Valley Retina Institute P.A. | McAllen | Texas | 78503 | — |
| Medical Center Ophthalmology Associates | San Antonio | Texas | 78240 | — |
| Univ of Virginia Ophthalmology | Charlottesville | Virginia | 22903 | — |
| Karalis Johnson Retina Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06771271, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 13, 2025 · Synced Nov 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.